Seizure recurrence following the first unprovoked seizure: Risk factors among children in UAE

Dina Amin Saleh1,2, Abeera Hassan1

  • 1Division of Neurology, American Center for Psychiatry and Neurology, Abu Dhabi, UAE.

Insights

Most children and adolescents with a first unprovoked seizure experience recurrence, especially within six months. Risk factors include focal seizures and abnormal EEG or MRI results, highlighting the need for early monitoring and assessment.

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • First unprovoked seizures in pediatric and adolescent populations require understanding recurrence patterns.
  • Identifying predictors of seizure recurrence is crucial for effective patient management and prognosis.

Purpose of the Study:

  • To identify significant risk factors associated with seizure recurrence in pediatric and adolescent patients in Abu Dhabi, UAE.
  • To analyze the timing and overall risk of seizure recurrence after a first unprovoked seizure.

Main Methods:

  • Retrospective study of 317 pediatric and adolescent patients with a first unprovoked seizure (March 2016 - March 2020).
  • Minimum one-year follow-up data collected to assess seizure recurrence.
  • Analysis of clinical factors, electroencephalogram (EEG), and magnetic resonance imaging (MRI) findings.

Main Results:

  • A high recurrence rate of 96.2% was observed, with 68.8% occurring within the first 6 months.
  • Significant risk factors for recurrence included focal seizures, symptomatic etiology, abnormal initial EEG, abnormal MRI, and co-existing neurological disorders.
  • The type of epileptiform activity on initial EEG did not predict recurrence. Overall 3-year recurrence risk reached 98.4%.

Conclusions:

  • Vigilant monitoring is essential, particularly in the early post-seizure period for pediatric and adolescent patients.
  • Initial EEG and MRI assessments are recommended, especially for remote symptomatic first unprovoked seizures.
  • Understanding recurrence patterns aids in optimizing management strategies for young epilepsy patients.

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
307
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341